DBV Technologies | DBVT - 流动资产



金融业
股票价格
USD
资产
USD 233.72M
现金及等价物
USD 194.17M
流动资产
USD 212.94M
流动负债
USD 58.03M
债务
USD 8.59M
股息收益率
USD 0
EBIT
USD -34.28M
EBITDA
USD -33.49M
员工
USD 104
EPS每股收益
USD -0.24
股本和储备
USD 168.77M
销售毛利
USD 2.77M
债务利息支出
USD 461K
利息收入
USD -0.32
贷款资金
USD 0
市值
USD 696.7M
净收入
USD -33.16M
营业费用
USD 37.05M
营业利润
USD -34.28M
普通股股本
USD 136.82M
税前利润
USD -33.16M
销售收入
USD 2.77M
销售和管理费用
USD 3.63M
贸易债权人
USD 39.82M
应收帐款人
USD 15.97M


流动资产 更改 日
Acadia Pharmaceuticals USD 1.1B 33.9M 2026-03
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
Amarin USD 626.02M 23.87M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
BioMarin Pharmaceutical USD 4.61B 651.58M 2026-03
DBV Technologies USD 212.94M 124.06M 2025-12
Esperion Therapeutics USD 459.46M 3.11M 2026-03
Galectin Therapeutics USD 27.29M 1.83M 2024-06
Halozyme Therapeutics USD 1B 177.83M 2026-03
Incyte USD 5.48B 460.36M 2026-03
Insmed USD 1.61B 181.04M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
United Therapeutics USD 2.87B 830.5M 2026-03